Migraine: new solutions for an invisible enemy

The 6 million Italians who suffer from migraines live between one attack and the constant fear of the next. This is what emerges from a research promoted by @teva_it and conducted by Elma Research.

The effects of migraines were investigated in 4 different areas: in the private sphere, in the public one, in the perception of the judgment of others and in the type of approach / reaction towards the disease. There are also 4 main types of impact highlighted: limitation, isolation, sense of guilt, difficulty in planning. The sense of guilt and the inability to make plans are central themes in the life of migraine sufferers: an aspect that should not be underestimated, in fact, is the anguish of those who constantly live in fear of the next crisis, often having already tried various drugs with side effects. that make everyday life not always easy.

For patients with the most severe forms of migraine, a targeted therapy is now available that allows you to significantly reduce the frequency of attacks, increasing the time lived fully, without the limitations imposed by the disease. Fremanezumab, a fully humanized monoclonal antibody developed specifically for the prevention of this disabling neurological disease - recently recognized as a social disease - is now reimbursed by the National Health System. Its efficacy is demonstrated in both episodic and chronic migraine forms. None of the treatments used so far for preventive purposes have been developed specifically to act on the causes of migraine: now, however, we have the opportunity to selectively intervene on one of the central mechanisms involved in the genesis of the disease.


“Every day Teva is committed to improving people's lives and has always worked alongside clinicians
to respond to the still unmet needs of patients ”says Roberta Bonardi, Senior Director BU
Innovative and GM Greece Teva. “It is estimated that less than 30% of migraine patients manage to manage hers
condition. Today, the availability of fremanezumab represents, for those patients who meet the criteria established by the Italian Medicines Agency, an important advance to improve their lives by combining the ability to prevent disease with a significant decrease in disability related to symptoms. A step forward for those suffering from this pathology, for greater awareness ".